Skip to main content

Characterization of Dispensing Patterns of Baricitinib, Ritlecitinib, and Upadacitinib in Patients with Alopecia, Crohn's Disease, Ulcerative Colitis, and Inflammatory Bowel Disease: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
baricitinib
ritlecitinib
upadacitinib
Description

In this request, we characterized dispensing patterns of newly initiated baricitinib indicated for alopecia, ritlecitinib indicated for alopecia, and upadacitinib indicated for Crohn's disease, ulcerative colitis, and inflammatory bowel disease, stratified by age and sex in the Sentinel Distributed Database (SDD).

The study period includes data from March 1, 2022 to January 31, 2024. We distributed this request to five Sentinel Data Partners on August 6, 2024. 

Deliverables (1)
Sentinel Modular Program Report: Characterization of Dispensing Patterns of Baricitinib, Ritlecitinib, and Upadacitinib in Patients with Alopecia, Crohn's Disease, Ulcerative Colitis, and Inflammatory Bowel Disease: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
March 1, 2022 - January 31, 2024
Analysis Type
Descriptive
Population / Cohort
All Individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Litfulo (Ritlecitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism & Stroke
Sentinel Drug Study: Rinvoq (Upadacitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and Thrombotic Stroke
Sentinel Drug Study: Olumiant (Baricitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke